Tag Archives: Abbvie’s

It’s not just pricing and patenting. Now, AbbVie’s taxes are the target of congressional scrutiny

AbbVie has spent years responding to a congressional probe over its drug pricing and patenting strategies, with the findings just becoming public late last month. Now, in a newly unveiled probe, congressional Democrats are zeroing in on the company’s tax payments.  In a letter to CEO Richard Gonzalez dated Wednesday, Sen. Ron Wyden, D-Oregon, chairman of the Senate… Read More »

Abbvie’s Rinvoq matches BMS’ Orencia in head-to-head rheumatoid arthritis trial

With megablockbuster Humira on the decline, AbbVie is hoping for big things from its next-gen JAK inhibitor Rinvoq. Now, in a head-to-head rheumatoid arthritis battle with Bristol Myers Squibb’s blockbuster Orencia, Rinvoq has come out on top. Rinvoq matched Bristol’s Orencia in easing rheumatoid arthritis patients’ symptoms at the 12-week mark and bested its older rival in patient remission rates, according to… Read More »